(SRPT) Sarepta Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.815m USD | Total Return: -53.3% in 12m
Avg Turnover: 55.7M
Qual. Beats: 1
Rev. Trend: 94.1%
Qual. Beats: 7
Warnings
Share dilution 25.2% YoY
Altman Z'' -3.62 < 1.0 - financial distress zone
Volatile Below Avwap Earnings
Tailwinds
No distinct edge detected
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical firm specializing in genetic medicine for rare diseases. The company’s portfolio primarily targets Duchenne muscular dystrophy (DMD) through RNA-targeted therapies-including EXONDYS 51, VYONDYS 53, and AMONDYS 45-and ELEVIDYS, an adeno-associated virus (AAV) based gene therapy. Its clinical pipeline extends to limb-girdle muscular dystrophy and other genetic conditions using RNA interference (RNAi) and gene therapy platforms.
Operating within the biotechnology sector, Sarepta utilizes a high-R&D business model characterized by significant upfront investment in proprietary platform technologies. To mitigate the high costs of clinical development and commercialization, the company maintains strategic licensing and collaboration agreements with global entities such as F. Hoffman-La Roche and Arrowhead Pharmaceuticals. Use ValueRay to evaluate how these partnerships impact the companys long-term valuation.
Headquartered in Cambridge, Massachusetts, the company has transitioned from a research-focused entity to a commercial organization with multiple FDA-approved products. This transition is typical for mature biotech firms that leverage orphan drug designations to secure market exclusivity and address unmet medical needs in small patient populations.
- FDA label expansion for Elevidys drives significant revenue growth in Duchenne market
- Commercial adoption of gene therapy portfolio offsets high research and development costs
- Strategic partnership with Roche provides critical international distribution and milestone payments
- Regulatory scrutiny of clinical trial data impacts long-term pipeline valuation and approvals
- Market penetration of exon-skipping treatments sustains baseline cash flow for genetic research
| Net Income: 65.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 23.50 > 1.0 |
| NWC/Revenue: 82.90% < 20% (prev 81.80%; Δ 1.10% < -1%) |
| CFO/TA 0.06 > 3% & CFO 175.3m > Net Income 65.1m |
| Net Debt (582.0m) to EBITDA (125.0m): 4.66 < 3 |
| Current Ratio: 4.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.9m) vs 12m ago 25.22% < -2% |
| Gross Margin: 62.39% > 18% (prev 0.82%; Δ 6.16k% > 0.5%) |
| Asset Turnover: 65.75% > 50% (prev 64.45%; Δ 1.30% > 0%) |
| Interest Coverage Ratio: 1.90 > 6 (EBITDA TTM 125.0m / Interest Expense TTM 42.1m) |
| A: 0.57 (Total Current Assets 2.31b - Total Current Liabilities 499.2m) / Total Assets 3.18b |
| B: -1.43 (Retained Earnings -4.55b / Total Assets 3.18b) |
| C: 0.02 (EBIT TTM 79.8m / Avg Total Assets 3.32b) |
| D: -2.72 (Book Value of Equity -4.55b / Total Liabilities 1.67b) |
| Altman-Z'' = -3.62 = D |
| DSRI: 0.77 (Receivables 547.9m/724.5m, Revenue 2.18b/2.23b) |
| GMI: 1.31 (GM 62.39% / 81.82%) |
| AQI: 0.85 (AQ_t 0.13 / AQ_t-1 0.15) |
| SGI: 0.98 (Revenue 2.18b / 2.23b) |
| TATA: -0.03 (NI 65.1m - CFO 175.3m) / TA 3.18b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of June 02, 2026, the stock is trading at USD 17.61 with a total of 2,780,227 shares traded.
Over the past week, the price has changed by +4.82%,
over one month by -18.05%,
over three months by +7.90% and
over the past year by -53.34%.
Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22 | 24.9% |
P/E Trailing = 49.1286
P/E Forward = 5.423
P/S = 0.8311
P/B = 1.17
P/EG = 159.25
Revenue TTM = 2.18b USD
EBIT TTM = 79.8m USD
EBITDA TTM = 125.0m USD
Long Term Debt = 838.2m USD (from longTermDebt, last quarter)
Short Term Debt = 11.2m USD (from shortTermDebt, last fiscal year)
Debt = 1.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 198.5m
Net Debt = 582.0m USD (calculated: Debt 1.24b - CCE 653.2m)
Enterprise Value = 2.40b USD (1.82b + Debt 1.24b - CCE 653.2m)
Interest Coverage Ratio = 1.90 (Ebit TTM 79.8m / Interest Expense TTM 42.1m)
EV/FCF = 22.38x (Enterprise Value 2.40b / FCF TTM 107.1m)
FCF Yield = 4.47% (FCF TTM 107.1m / Enterprise Value 2.40b)
FCF Margin = 4.91% (FCF TTM 107.1m / Revenue TTM 2.18b)
Net Margin = 2.98% (Net Income TTM 65.1m / Revenue TTM 2.18b)
Gross Margin = 62.39% ((Revenue TTM 2.18b - Cost of Revenue TTM 821.4m) / Revenue TTM)
Gross Margin QoQ = 83.67% (prev 9.98%)
Tobins Q-Ratio = 0.75 (Enterprise Value 2.40b / Total Assets 3.18b)
Interest Expense / Debt = 3.41% (Interest Expense 42.1m / Debt 1.24b)
Taxrate = 3.56% (12.2m / 343.2m)
NOPAT = 77.0m (EBIT 79.8m * (1 - 3.56%))
Current Ratio = 4.63 (Total Current Assets 2.31b / Total Current Liabilities 499.2m)
Debt / Equity = 0.82 (Debt 1.24b / totalStockholderEquity, last quarter 1.51b)
Debt / EBITDA = 4.66 (Net Debt 582.0m / EBITDA 125.0m)
Debt / FCF = 5.43 (Net Debt 582.0m / FCF TTM 107.1m)
Total Stockholder Equity = 1.33b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.96% (Net Income 65.1m / Total Assets 3.18b)
RoE = 1.11% (Net Income TTM 65.1m / Total Stockholder Equity 5.88b)
RoCE = 1.19% (EBIT 79.8m / Capital Employed (Equity 5.88b + L.T.Debt 838.2m))
RoIC = 2.86% (NOPAT 77.0m / Invested Capital 2.69b)
WACC = 6.50% (E(1.82b)/V(3.05b) * Re(8.69%) + D(1.24b)/V(3.05b) * Rd(3.41%) * (1-Tc(0.04)))
Discount Rate = 8.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.89 | Cagr: 6.60%
[DCF] Terminal Value 75.44% ; FCFF base≈107.1m ; Y1≈107.6m ; Y5≈114.0m
[DCF] Fair Price = 11.28 (EV 1.77b - Net Debt 582.0m = Equity 1.19b / Shares 105.6m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.53 | # QB: 1
Revenue Correlation: 94.14 | Revenue CAGR: 39.05% | SUE: 4.0 | # QB: 7
EPS current Quarter (2026-06-30): EPS=0.49 | Chg30d=-55.48% | Revisions=-54% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.50 | Chg30d=-18.08% | Revisions=-8% | Analysts=9
EPS current Year (2026-12-31): EPS=4.83 | Chg30d=+20.94% | Revisions=+38% | GrowthEPS=+195.6% | GrowthRev=-16.4%
EPS next Year (2027-12-31): EPS=2.73 | Chg30d=-9.30% | Revisions=-12% | GrowthEPS=-43.6% | GrowthRev=-22.5%
[Analyst] Revisions Ratio: -54%